(Press-News.org) COLUMBUS, Ohio – A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
In this Ohio State University study, the drug treatment also was associated with smaller tumors – an unexpected result.
The drug, zoledronic acid, is known by the brand name Zometa. It is designed to inhibit bone resorption, the breaking down of bone caused by the release of a specific kind of cell.
Oral squamous cell carcinoma accounts for about 90 percent of all tumors in the mouth. The five-year survival rate for this form of cancer is 61 percent for all stages combined, according to the National Cancer Institute.
When these tumors form in the gums, their growth in the limited space of the mouth leads to bone loss in the jaw. In turn, bone erosion stimulates the cancer to grow. Scientists call this phenomenon, driven in part by the release of cancer stimulatory compounds from bone, a vicious cycle that occurs in this and other forms of cancer. So even though bone loss itself is not life-threatening, loss of bone means the tumor is continuing to grow.
"The goal is to stop the vicious cycle," said Thomas Rosol, professor of veterinary biosciences at Ohio State and senior author of the study. "Chemotherapy, radiation and surgery are all used to treat head and neck cancers. Zoledronic acid is a very safe drug and all it does is block bone resorption, so patients could receive all of the standard treatments, and this drug could be added as an additional benefit. That's the overall concept."
Further animal and human studies would be required to determine the proper dose and assure the drug's safety and effectiveness, he said.
The research is published in a recent issue of the journal Cancer Research.
The researchers injected mice with oral squamous cell carcinoma cells from cats to create a disease model for the study. They assigned mice to one of four groups: animals with and without tumors that received a placebo treatment, and mice with and without tumors that received a zoledronic acid treatment.
Animals treated with the drug retained twice as much total bone as did mice with cancer that were untreated. The bone that was present after treatment was a combination of reduced loss of pre-existing bone and an increase in new bone formation, said Rosol, also an investigator in Ohio State's Comprehensive Cancer Center.
Powerful images of the animals' skulls revealed that the bone loss was so severe in some untreated animals with cancer that their tooth roots were exposed. In comparison, animals with cancer that received the drug retained enough bone to keep the tooth roots covered with bone. Overall, on average, mice with cancer that received the drug treatment retained enough bone to match the amount of total bone in mice without tumors.
"When there is bone loss, there is formation of new bone to try to compensate for the loss," Rosol said. "The new bone is not perfect, but importantly, drug treatment prevented loss of both pre-existing normal bone and the new bone that formed."
The retention of bone was attributed at least in part to the drug's ability to reduce the number of activated osteoclasts by 52 percent at sites where the tumor and bone met. Osteoclasts are the cells that are responsible for bone resorption.
The cancer cells that were injected into the mice had been altered to contain a protein that creates light so the scientists could track development of the tumors. At day 28, the tumors treated with zoledronic acid were, on average, at least 14 percent smaller than were tumors that were left untreated.
"With less bone resorption, there might be less stimulation of the tumor," Rosol said. "So if you slow down bone loss, it's not as suitable an environment for the cancer to progress. We were not trying to cure the cancer, but what we're showing is that even with no other therapy than zoledronic acid, the disease is better."
Rosol also noted that in the course of this research, an Ohio State graduate student developed the first mouse model of oral squamous cell carcinoma that leads to bone loss. Chelsea Martin, lead author of the study and a doctoral student in veterinary biosciences at the time, determined which kinds of cancer cells to use and where to inject them to produce the same cancer development in mice that is experienced by human patients.
"This new model mimics the disease very well," Rosol said.
It turns out that oral squamous cell carcinoma is also a common disease in cats. Knowing this, Martin, now a postdoctoral researcher in molecular and cellular biochemistry at Ohio State, produced the animal disease model by injecting oral cancer cells from a cat into the gums above the front teeth of mice whose immune systems were suppressed.
Rosol and colleagues plan to continue the research by testing the effects of zoledronic acid when it is combined with anticancer drugs in animals with head and neck cancer.
INFORMATION:
This work was supported by grants from the Morris Animal Foundation, the National Cancer Institute and the National Institutes of Health.
Additional co-authors of the paper include Jillian Werbeck, Nanda Thudi, Lisa Lanigan and Tobie Wolfe of veterinary biosciences, and Ramiro Toribio of veterinary clinical sciences, all at Ohio State.
Contact: Thomas Rosol, (614) 292-4265; rosol.1@osu.edu
Written by Emily Caldwell, (614) 292-8310; caldwell.151@osu.edu
Study: Osteoporosis drug reduces bone loss, tumor size in oral cancer
2010-12-14
ELSE PRESS RELEASES FROM THIS DATE:
Defective cell surface 'glue' is key to tumor invasion
2010-12-14
A remarkable discovery into how tumour cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells. A new study by scientists at the Montreal Neurological Institute and Hospital of McGill University reveals that the surface of aggressive tumour cells lack the strong molecular 'glue' responsible for binding normal cells together. This allows tumour cells to break away, detach from their neighbors, and spread to other regions of the body.
Certain proteins, called cadherins, are located on the surface of ...
Research examines gender gaps in immigrant health
2010-12-14
DURHAM, N.C. – A key focus of the health care debate has involved immigrants and their impact on the U.S. health care system.
A new study shows that Mexican Americans most integrated into the culture -- including those born in the United States -- are more likely to require resources to manage their health conditions than more recent immigrants to the U.S., according to researchers at Duke University, Rice University and the University of Colorado Denver.
"The implications of these findings run counter to the popular belief that recent immigrant arrivals are taxing ...
Study probes link between magnetism, superconductivity
2010-12-14
HOUSTON -- (Dec. 13, 2010) -- European and U.S. physicists this week are offering up the strongest evidence yet that magnetism is the driving force behind unconventional superconductivity. The findings by researchers from Rice University, the Max Planck Institute for Chemical Physics of Solids (MPI-CPfS) in Dresden, Germany, and other institutions were published online today in Nature Physics.
The findings follow more than three decades of research by the team that discovered unconventional superconductivity in 1979. That breakthrough, which was led by MPI-CPfS Director ...
Study shows how flu infections may prevent asthma
2010-12-14
Boston, Mass. - In a paper that suggests a new strategy to prevent asthma, scientists at Children's Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma. The same protective effect was achieved by treating young mice with compound isolated from the bacterium Helicobacter pylori (H. pylori), a bacterium that colonizes the stomach and is best known for causing ulcers and increasing the risk of gastric cancers.
The findings, published online December 13 in the ...
Early settlers rapidly transformed New Zealand forests with fire
2010-12-14
BOZEMAN, Mont. -- New research indicates that the speed of early forest clearance following human colonisation of the South Island of New Zealand was much faster and more intense than previously thought.
Charcoal recovered from lake-bed sediment cores show that just a few large fires within 200 years of initial colonization destroyed much of the South Island's lowland forest. Grasslands and shrubland replaced the burnt forest and smaller fires prevented forests from returning.
The findings - by an international team led by Dave McWethy and Cathy Whitlock from Montana ...
Recovering from job loss: Most report few long-term psychological effects, study finds
2010-12-14
WASHINGTON – Losing a job is a profoundly distressing experience, but the unemployed may be more resilient than previously believed – the vast majority eventually end up as satisfied with life as they were before they lost their jobs, according to a new analysis published by the American Psychological Association.
"Unemployment rates continue to be historically high in the United States and other countries," said the study's lead author, Isaac Galatzer-Levy, PhD, who is now at New York University School of Medicine. "There's a real concern that this will have long-term ...
When it comes to selecting a mate, the eyes have it: Queen's University study
2010-12-14
For the first time ever, scientists have found a difference in the way males and females of the same species of vertebrate see things – and that sexes likely use that difference to select their mates.
Queen's PhD candidate Shai Sabbah, a Vanier Scholar, led a team of researchers who found that male and female cichlid fishes not only see things differently, but detect light in different ways as well.
"It is difficult to say what colour attracts the female the most, but we know that if we manipulate the colour of the fish by changing the light in the environment, the ...
We spend more time sick now than a decade ago
2010-12-14
Increased life expectancy in the United States has not been accompanied by more years of perfect health, reveals new research published in the December issue of the Journal of Gerontology.
Indeed, a 20-year-old today can expect to live one less healthy year over his or her lifespan than a 20-year-old a decade ago, even though life expectancy has grown.
From 1970 to 2005, the probability of a 65-year-old surviving to age 85 doubled, from about a 20 percent chance to a 40 percent chance. Many researchers presumed that the same forces allowing people to live longer, including ...
UCSF 'fountain of youth' pill could restore aging immune system
2010-12-14
UCSF researchers have identified an existing medication that restores key elements of the immune system that, when out of balance, lead to a steady decline in immunity and health as people age.
The team found that extremely low doses of the drug lenalidomide can stimulate the body's immune-cell protein factories, which decrease production during aging, and rebalance the levels of several key cytokines – immune proteins that either attack viruses and bacteria or cause inflammation that leads to an overall decline in health.
The initial study, which was designed to define ...
Early years' initiatives, such as Sure Start, are failing the poor, eight-year study shows
2010-12-14
Early years initiatives for pre-school children are not delivering improvements in language and numeracy development, according to leading education experts.
Experts, conducting one of the largest surveys to date of the development of 117,000 children starting primary school in England over eight years, found that despite a raft of early years' initiatives, such as 'Sure Start', basic levels of development in early reading, vocabulary and maths have remained largely unchanged.
Researchers from the Centre for Evaluation and Monitoring (CEM) at Durham University who ...